Skip to main content
Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze SYRE Spyre Therapeutics, Inc.: https://finlab.finance/en/setup?stock=SYRE”

Run AI in browser

SYRE

Spyre Therapeutics, Inc. Healthcare As of 2026-06-18
Quality Weak
Valuation Cheaper
Risk High vol
Active signals Active 52-week adjusted-price high Top-quintile 6-month momentum
88.34 Close (USD)
+109.24% 60-day
  • Quality is weaker than peers. Operating margin is only around the 9th percentile. TTM ROE is about -26.8%.
  • Valuation is cheaper than most peers. TTM P/E is in the 7th percentile, lower than most liquid US common stocks.
  • Recent volatility is elevated. 60-day annualized volatility is in the 83th percentile. Average 20-day dollar volume is about $84.5M.
  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Factor profile

Factor radar Neutral Valuation
45
ValuationQualityGrowthMomentumRisk / liquidity

Valuation

Indicators in this group are ranked by market percentile; lower valuation and volatility are better.

45 Neutral
TTM P/E -40.34
Cheap
Price / book 45.57
Expensive
Free-cash-flow yield (%) -0.61
Average

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

10 historical occurrences (since 2018-03-08)
Average forward return after 52-week adjusted-price high。20-day: Win 88.9%, Sample 9, Median +15.33%, Excess +12.57%, Beat mkt rate 88.9%；60-day: Win 75%, Sample 8, Median +26.88%, Excess +24.66%, Beat mkt rate 75%；120-day: Win 71.4%, Sample 7, Median +12.59%, Excess +20.11%, Beat mkt rate 42.9%

120 days after: historical avg +28.75%

20-day +14.91%
60-day +30.97%
120-day +28.75%
20-day
60-day
120-day
Win
88.9%
75%
71.4%
Sample
9
8
7
Median
+15.33%
+26.88%
+12.59%
Excess
+12.57%
+24.66%
+20.11%
Beat mkt rate
88.9%
75%
42.9%

Over 7 occurrences, 120-day forward avg gained 28.75%, beat the market by 20.11 pts; win rate 71.4%.

Top-quintile 6-month momentum

Active · now 96.52542372881356%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

13 historical occurrences (since 2017-12-04)
Average forward return after Top-quintile 6-month momentum。20-day: Win 46.2%, Sample 13, Median -1.93%, Excess -5.44%, Beat mkt rate 46.2%；60-day: Win 30.8%, Sample 13, Median -17.17%, Excess -12.4%, Beat mkt rate 23.1%；120-day: Win 46.2%, Sample 13, Median -11.45%, Excess +6.69%, Beat mkt rate 30.8%

120 days after: historical avg +14.22%

20-day -3.56%
60-day -10.06%
120-day +14.22%
20-day
60-day
120-day
Win
46.2%
30.8%
46.2%
Sample
13
13
13
Median
-1.93%
-17.17%
-11.45%
Excess
-5.44%
-12.4%
+6.69%
Beat mkt rate
46.2%
23.1%
30.8%

Over 13 occurrences, 120-day forward avg gained 14.22%, beat the market by 6.69 pts; win rate 46.2%.

Market-wide momentum baseline

Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

6 times historically; 60-day forward avg +1.72%, win rate 33.3%, beating the market by +0.09 pts on average.

Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze SYRE Spyre Therapeutics, Inc.: https://finlab.finance/en/setup?stock=SYRE”

Run AI in browser

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.